Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults
Phase 1
Completed
- Conditions
- Food HypersensitivityHypersensitivityImmediate HypersensitivityPeanut Hypersensitivity
- Interventions
- Biological: E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3
- First Posted Date
- 2009-02-25
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Allertein Therapeutics, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT00850668
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Mount Sinai Medical Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath